MYC & BCL2 or BCL6 co-expression in DLBCL Zawam et al.
91
Accordingly, appropriate first-line treatment could be
modified to overcome the dismal response of these cases
to the standard R-CHOP regimen.
Conflicts of interest
There are no conflicts of interest.
References
Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N (2011). Clinical
prognostic factors of diffuse large B cell non-Hodgkin lymphoma:
a retrospective study. J Egypt Natl Canc Inst 23:17–24.
Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al.
(2010). Concordance between four European centres of PET reporting
criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl
Med Mol Imaging 37:1824–1833.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al.
(2014). Recommendations for initial evaluation, staging, and response
assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classifica-
tion. J Clin Oncol 32:3059–3068.
Green T, Young K, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. (2012).
Immunohistochemical double hit score is a strong predictor of outcome in patients
with diffuse large B cell lymphoma treated with rituximab plus cyclophosphamide,
doxorubicin, vincristine and, predinisone. J Clin Oncol 30:3460–3467.
Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, et al. (2016). Relapsed or
refractory double-expressor and double-hit lymphomas have inferior progression-
free survival after autologous stem-cell transplantation. J Clin Oncol 68:2740.
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. (2013). MYC
status in concert with BCL2 and BCL6 expression predicts outcome in
diffuse large B-cell lymphoma. Blood 121:2253–2263.
Hu S, Xu-Monette Z, Tzankov A, Green T, Wu L, Balasubramanyam A, et al.
(2013). MYC/BCL2 protein coexpression contributes to the inferior survival of
activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates
high-risk gene expression signatures: a report from The International DLBCL
Rituximab-CHOP Consortium Program. Blood 121:4021–4031.
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al.
(2012). Concurrent expression of MYC and BCL2 in diffuse large B-cell
lymphoma treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone. J Clin Oncol 30:3452–3459.
Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H, et al.
(2016). MYC translocation and/or BCL 2 protein expression are associated
with poor prognosis in diffuse large B cell lymphoma. Cancer Sci
107:853–861.
Kobayashi T, Tsutsumi Y, Sakamoto N, Nagoshi H, Yamamoto-Sugitani M,
Shimura Y, et al. (2012). Double-hit lymphomas constitute a highly aggressive
subgroup in diffuse large B-cell lymphomas in the era of rituximab. Jpn J Clin
Oncol 42:1035–1042.
Li S, Young KH, Medeiros LJ (2018). Diffuse large B-cell lymphoma. Pathology
50:74–87.
Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioliet C, et al.
(2016). High-dose chemotherapy followed by autologous transplantation may
overcome the poor prognosis of diffuse large B-cell lymphoma patients with
MYC/BCL2 co-expression. Blood Cancer J 6:e491.
Perry AM, Alvarado-Berna lY, Laurini JA, Smith LM, Slack GW, Tan KL, et al.
(2014). MYC and BCL2 protein expression predicts survival in patients with
diffuse large B-cell lymphoma treated with rituximab. Br J Haematol
165:382–391.
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. (2014).
Impact of induction regimen and stem cell transplantation on outcomes in
patients with double hit lymphoma: a large multicenter retrospective analysis.
Blood 124:2354–2361.
Pfreundschuh M, Truemper L, Gill D, Osterborg A, Pettengell R, Trneny M, et al.
(2004). First analysis of the completed Mabthera International (Mint) Trial in
young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition
of rituximab to a CHOP-like regimen significantly improves outcome of all
patients with the identification of a very favorable subgroup with IPI = O and
no bulky disease. Blood 104:48a.
Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. (2005).
Introduction of combined CHOP plus rituximab therapy dramatically improved
outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol
23:5027–5033.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. (2007).
The revised International Prognostic Index (R-IPI) is a better predictor of
outcome than the standard IPI for patients with diffuse large B-cell lymphoma
treated with R-CHOP. Blood 109:1857–1861.
Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. (2010).
Racial differences in the presentation and outcomes of diffuse large B-cell
lymphoma in the United States. Cancer 117:2530–2540.
Smith SM (2017a). Aggressive B-cell lymphoma: the double-hit and double-
expressor phenotypes. Clin Adv Hematol Oncol 15:40–42.
Smith SM (2017b). Impact of double-hit and double-expressor phenotypes in
relapsed aggressive B-cell lymphomas treated with autologous hematopoietic
stem cell transplantation. J Clin Oncol 35:1–3.
Swerdlow S (2014). Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL
and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc
Hematol Educ Program 1:90–99.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. (2016).
The 2016 revision of the World Health Organization classification of lymphoid
neoplasms. Blood 127:2375–2390.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993). A
predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med
329:987–994.
Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al.
(2014). Rearrangements of MYC gene facilitate risk stratification in diffuse
large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol
27:958–971.
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, et al.
(2001). Phase II study of rituximab in combination with chop chemotherapy in
patients with previously untreated, aggressive non-Hodgkin’s lymphoma.
J Clin Oncol 19:389–397.
Yan LX, Liu YH, Luo DL, Zhang F, Cheng Y, Luo XL, et al. (2014). MYC expression
in concert with BCL2 and BCL6 expression predicts outcome in chinese
patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS
One 8:e104068.
Ye Q, Zijun Y, Xu-Monette ZY, Deng L, Wang X, Manyam GC, et al. (2015).
Prognostic impact of concurrent MYC and BCL6 rearrangements and
expression in de novo diffuse large B-cell lymphoma. Oncotarget 7:2401–2416.